NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis $13.95 +0.12 (+0.87%) Closing price 04:00 PM EasternExtended Trading$13.96 +0.01 (+0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enanta Pharmaceuticals Stock (NASDAQ:ENTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enanta Pharmaceuticals alerts:Sign Up Key Stats Today's Range$13.79▼$14.4150-Day Range$12.08▼$15.4652-Week Range$5.55▼$17.15Volume141,313 shsAverage Volume202,214 shsMarket Capitalization$405.67 millionP/E RatioN/ADividend YieldN/APrice Target$20.29Consensus RatingModerate Buy Company Overview Enanta Pharmaceuticals, Inc. is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens. Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections. Its lead RSV program, EDP-938, is an orally administered inhibitor designed to block viral replication and is being evaluated in Phase 2 clinical trials for both adult and pediatric populations. In addition to RSV, Enanta is advancing preclinical candidates against hepatitis B virus (HBV) and other respiratory pathogens, seeking to apply its structure-based drug design approach to a broader array of infectious diseases. Founded in 1997 by a team of chemists and virologists, Enanta has established collaborative relationships with large pharmaceutical firms to accelerate the development and commercialization of its antiviral compounds. These partnerships have provided non-dilutive funding and clinical development support, while allowing Enanta to retain rights to key programs in certain territories. Under the leadership of President and Chief Executive Officer Jay R. Luly, the company continues to expand its scientific capabilities and manufacturing collaborations. Enanta maintains research facilities in Massachusetts and works with contract development and manufacturing organizations to advance its pipeline. With a focus on unmet medical needs in viral diseases, Enanta aims to bring novel oral therapies to patients worldwide.AI Generated. May Contain Errors. Read More Enanta Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreENTA MarketRank™: Enanta Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat, and ranked 733rd out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEnanta Pharmaceuticals has a consensus price target of $20.29, representing about 45.4% upside from its current price of $13.95.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Enanta Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to remain at ($1.98) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enanta Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.39% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 18.82, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently increased by 2.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.48% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enanta Pharmaceuticals' insider trading history. Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTA Stock News HeadlinesEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200-Day Moving Average - Time to Sell?May 22 at 4:43 AM | americanbankingnews.comEnanta Pharmaceuticals Announces Public Stock OfferingApril 11, 2026 | msn.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 22 at 1:00 AM | Porter & Company (Ad)Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory ...April 7, 2026 | finanznachrichten.deEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID ...April 7, 2026 | finance.yahoo.comEnanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)March 30, 2026 | finance.yahoo.comEnanta Advances Federal Circuit Appeal in Paxlovid Patent CaseMarch 26, 2026 | tipranks.comEnanta Pharmaceuticals (ENTA) Gets a Buy from J.P. MorganMarch 8, 2026 | theglobeandmail.comSee More Headlines ENTA Stock Analysis - Frequently Asked Questions How have ENTA shares performed this year? Enanta Pharmaceuticals' stock was trading at $15.77 at the start of the year. Since then, ENTA shares have decreased by 11.5% and is now trading at $13.95. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) posted its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.01. The biotechnology company had revenue of $17.16 million for the quarter, compared to analysts' expectations of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative trailing twelve-month return on equity of 64.04%. When did Enanta Pharmaceuticals IPO? Enanta Pharmaceuticals (ENTA) raised $60 million in an initial public offering on Thursday, March 21st 2013. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Who are Enanta Pharmaceuticals' major shareholders? Top institutional investors of Enanta Pharmaceuticals include Janus Henderson Group PLC (13.01%), Spruce Street Capital LP (3.21%), Renaissance Technologies LLC (2.29%) and Hillsdale Investment Management Inc. (1.50%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Tara Lynn Kieffer, Scott T Rottinghaus, Kathleen S Capps and Terry Vance. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG). Company Calendar Last Earnings5/11/2026Today5/22/2026Next Earnings (Confirmed)8/10/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ENTA's financial health is in the Green zone, according to TradeSmith. ENTA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTA CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees160Year Founded1995Price Target and Rating Average Price Target for Enanta Pharmaceuticals$20.29 High Price Target$28.00 Low Price Target$12.00 Potential Upside/Downside+45.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$81.89 million Net Margins-89.56% Pretax Margin-89.42% Return on Equity-64.04% Return on Assets-20.22% Debt Debt-to-Equity RatioN/A Current Ratio3.84 Quick Ratio3.84 Sales & Book Value Annual Sales$65.32 million Price / Sales6.21 Cash FlowN/A Price / Cash FlowN/A Book Value$4.01 per share Price / Book3.48Miscellaneous Outstanding Shares29,080,000Free Float25,740,000Market Cap$405.67 million OptionableOptionable Beta1.01 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ENTA) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredOne algorithm, 17 years, nearly 2,000% total returnsA physicist in Dublin claims his AI algorithm has beaten the market for 17 consecutive years - with nearly 2,0...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredRevealed: The Best Kept Secrets On Wall StreetTom Busby, founder of the Diversified Trading Institute, is giving away his 'Little Black Book' - a collection...DTI Trader | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
